^
Association details:
| Biomarker: | CD14 overexpression |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Biomarkers Predicting Venetoclax Sensitivity and Strategies for Venetoclax Combination Treatment
Published date:
11/01/2018
Excerpt:
...venetoclax-palbociclib could circumvent venetoclax resistance to treat patients with high CLEC7A and/or CD14 expression....In summary, we have identified that CD14 and/or CLEC7A could be used as biomarkers to predict venetoclax sensitivity in AML…
DOI:
https://doi.org/10.1182/blood-2018-175
